Wave Life Sciences Ltd.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on designing, developing, and commercializing ribonucleic acid (RNA) medicines. Its proprietary PRISM platform combines multiple modalities, chemistry innovation, and human genetics insights to create therapies for both rare and prevalent disorders. Key pipeline candidates include WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 targeting obesity via INHBE silencing, WVE-008 for liver disease, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington's disease. The company also collaborates with GlaxoSmithKline and Takeda on oligonucleotide therapeutics, and with Asuragen on companion diagnostics for Huntington's disease programs.

Wave Life Sciences Ltd. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol WVE. Its shares trade in US Dollars (USD). The company is headquartered in Singapore but its stock is traded on a US exchange, making it accessible to international investors. The listing on NasdaqGM provides liquidity and visibility within the US capital markets.

Wave Life Sciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing RNA-based medicines for a range of diseases. The biotechnology industry is characterized by high research and development costs, long product development cycles, and significant regulatory oversight. Wave's specialization in RNA therapeutics and its PRISM platform position it within the broader biotech landscape targeting genetic and rare disorders.

Wave Life Sciences Ltd. is headquartered in Singapore, though it operates as a global biotechnology company. Its research and development efforts target both rare and prevalent disorders, with clinical programs addressing conditions such as alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, Huntington's disease, and liver disease. The company collaborates with major pharmaceutical firms like GlaxoSmithKline and Takeda, indicating a reach beyond Singapore into global markets, particularly the US and Europe. Its stock is traded on the Nasdaq in the US, reflecting a primary focus on the American capital markets.

Wave Life Sciences has a diverse pipeline of RNA-based therapeutics. Notable candidates include WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated siRNA targeting INHBE mRNA for obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for liver disease; WVE-N531, an exon splicing oligonucleotide for Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for Huntington's disease. The company has collaboration agreements with GlaxoSmithKline for oligonucleotide therapeutics, with Takeda for CNS disorders, and with Asuragen for companion diagnostics in Huntington's disease programs. These partnerships help advance its pipeline and expand its therapeutic reach.